Bio-Rad Laboratories/$BIO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Bio-Rad Laboratories
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
Ticker
$BIO
Sector
Primary listing
NYSE
Industry
Life Sciences Tools & Services
Headquarters
Employees
7,700
ISIN
US0905722072
Website
BIO Metrics
BasicAdvanced
$6.7B
-
-$77.10
1.12
-
Price and volume
Market cap
$6.7B
Beta
1.12
52-week high
$373.69
52-week low
$211.43
Average daily volume
415K
Financial strength
Current ratio
5.994
Quick ratio
4.143
Long term debt to equity
19.867
Total debt to equity
20.503
Interest coverage (TTM)
5.64%
Profitability
EBITDA (TTM)
426.8
Gross margin (TTM)
53.64%
Net profit margin (TTM)
-85.16%
Operating margin (TTM)
10.79%
Effective tax rate (TTM)
21.31%
Revenue per employee (TTM)
$330,000
Management effectiveness
Return on assets (TTM)
1.55%
Return on equity (TTM)
-27.51%
Valuation
Price to revenue (TTM)
2.689
Price to book
1.01
Price to tangible book (TTM)
1.13
Price to free cash flow (TTM)
20.579
Free cash flow yield (TTM)
4.86%
Free cash flow per share (TTM)
1,183.12%
Growth
Revenue change (TTM)
-2.46%
Earnings per share change (TTM)
591.77%
3-year revenue growth (CAGR)
-4.26%
10-year revenue growth (CAGR)
1.74%
3-year earnings per share growth (CAGR)
193.89%
10-year earnings per share growth (CAGR)
36.52%
What the Analysts think about BIO
Analyst ratings (Buy, Hold, Sell) for Bio-Rad Laboratories stock.
Bulls say / Bears say
Bio-Rad Laboratories reported Q1 2025 earnings of $2.54 per share, surpassing the consensus estimate of $1.73, indicating strong operational performance. (Nasdaq)
The company's clinical diagnostics unit, its largest revenue segment, saw a 5.6% increase in sales to $388.8 million in Q3 2024, reflecting robust demand. (Reuters)
Analysts have set a median 12-month price target of $367.50 for Bio-Rad Laboratories, suggesting potential upside from current levels. (ETF Daily News)
Bio-Rad Laboratories revised its 2024 financial outlook downward, now expecting a revenue decline of 2.5%-4%, compared to previous growth projections of 1%-2.5%. (Seeking Alpha)
The company's life science segment reported a 17.1% decrease in sales to $263.5 million in Q3 2024, primarily due to reduced spending in the biotech sector and sluggish demand from China. (Benzinga)
Bio-Rad Laboratories' stock has declined approximately 25.7% since the beginning of the year, underperforming the S&P 500's decline of 5.3%. (Nasdaq)
Data summarised monthly by Lightyear AI. Last updated on 5 Jun 2025.
BIO Financial Performance
Revenues and expenses
BIO Earnings Performance
Company profitability
BIO News
AllArticlesVideos
Bio-Rad's Management to Host Investor Meetings During Jefferies Global Healthcare Conference
Business Wire·4 weeks ago
Bio-Rad's Management to Participate in Fireside Chat During 2025 RBC Capital Markets Global Healthcare Conference
Business Wire·2 months ago
Bio-Rad Reports First-Quarter 2025 Financial Results
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Bio-Rad Laboratories stock?
Bio-Rad Laboratories (BIO) has a market cap of $6.7B as of June 27, 2025.
What is the P/E ratio for Bio-Rad Laboratories stock?
The price to earnings (P/E) ratio for Bio-Rad Laboratories (BIO) stock is 0 as of June 27, 2025.
Does Bio-Rad Laboratories stock pay dividends?
No, Bio-Rad Laboratories (BIO) stock does not pay dividends to its shareholders as of June 27, 2025.
When is the next Bio-Rad Laboratories dividend payment date?
Bio-Rad Laboratories (BIO) stock does not pay dividends to its shareholders.
What is the beta indicator for Bio-Rad Laboratories?
Bio-Rad Laboratories (BIO) has a beta rating of 1.12. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.